Nedd4 activators represent a diverse chemical class that exert their primary biological effect by modulating the activity of the E3 ubiquitin-protein ligase known as Neural precursor cell expressed, developmentally down-regulated 4, or Nedd4. This particular ligase is a crucial component in the ubiquitin-proteasome system, which is responsible for tagging specific proteins for degradation and thus maintaining cellular protein homeostasis. The chemical agents within the Nedd4 activator class are characterized by their ability to enhance the enzymatic function of Nedd4, often by inducing its phosphorylation state. This phosphorylation can lead to an increase in the ligase's substrate recognition and ubiquitination activity. The spectrum of Nedd4 activators includes various biomolecules, such as growth factors, hormones, and small-molecule inhibitors, each interacting with unique cellular pathways but converging on the modulation of Nedd4.
The biochemical pathways engaged by these activators are complex and varied, with some acting directly on the Nedd4 protein and others exerting their effects indirectly through upstream signaling cascades. For instance, activators like EGF, insulin, and IGF-1 function through the activation of receptor tyrosine kinases, which in turn initiate the PI3K/AKT signaling pathway-a pathway that is well-established in its role in phosphorylating and activating various downstream targets, including Nedd4. Once activated, Nedd4 can attach ubiquitin to specific lysine residues on substrate proteins, marking them for degradation. On the other hand, certain small-molecule inhibitors, which ostensibly serve to impede enzymatic pathways, can paradoxically result in the upregulation of compensatory mechanisms within the cell that lead to the activation of Nedd4. These include inhibitors of MEK (such as PD98059 and U0126), PI3K (like LY294002 and Wortmannin), and mTOR (like Rapamycin), which, through complex feedback and regulatory loops within the cell's signaling networks, may inadvertently enhance the activity of the PI3K/AKT pathway and, consequently, Nedd4 activation.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Insulin | 11061-68-0 | sc-29062 sc-29062A sc-29062B | 100 mg 1 g 10 g | $156.00 $1248.00 $12508.00 | 82 | |
Insulin receptor activation stimulates the PI3K/AKT signaling pathway. AKT can phosphorylate Nedd4, which increases its ubiquitin ligase activity, promoting ubiquitination of target proteins. | ||||||
Bradykinin (1-3) | 23815-91-0 | sc-391193 sc-391193A sc-391193B | 5 mg 25 mg 100 mg | $154.00 $453.00 $1393.00 | ||
Bradykinin binds to its B2 receptor and can activate PLC, which in turn stimulates PKC. PKC has been shown to phosphorylate components of the ubiquitin-proteasome system, which can enhance the activity of Nedd4 indirectly. | ||||||
Ob (hBA-147) | sc-4912 | 1000 µg | $258.00 | 1 | ||
Leptin receptor signaling activates JAK2 and subsequently STAT3, which can interact with Nedd4. The interaction can promote Nedd4's E3 ligase activity, leading to increased ubiquitination of its substrates. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
PD98059 inhibits MEK, which indirectly can upregulate PI3K/AKT signaling by reducing negative feedback loops. Enhanced AKT activity can lead to phosphorylation and activation of Nedd4. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002, as a PI3K inhibitor, can modulate the activity of PI3K/AKT pathway. Paradoxical upregulation of AKT signaling upon PI3K inhibition has been noted, which could indirectly enhance Nedd4 activity. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $64.00 $246.00 | 136 | |
U0126 inhibits MEK1/2 leading to potential compensatory upregulation of other pathways including the PI3K/AKT pathway. This upregulation could enhance the phosphorylation and activity of Nedd4. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
Wortmannin inhibits PI3K leading to complex feedback loops that can result in the activation of compensatory mechanisms, potentially increasing PI3K/AKT signaling and enhancing Nedd4 activity. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Rapamycin inhibits mTOR, which can lead to a reduction in the negative feedback on the PI3K/AKT pathway. As a result, AKT can be upregulated, potentially enhancing the activity of Nedd4 through phosphorylation. | ||||||